Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21636241 | 0.84 | HIF1A (0.43) | CCNA2CDK2CCNA1SHMT2 | |
| SCHEMBL21625152 | 0.78 | SHMT2 (0.48) | SHMT2IKBKB | |
| SCHEMBL21636277 | 0.75 | GRIA2 (0.37) | CCNA2CDK2CCNA1SHMT2 | |
| SCHEMBL21625134 | 0.69 | PIK3CD (0.49) | F10SHMT2IKBKB | |
| SCHEMBL21625121 | 0.66 | SHMT2 (0.47) | CCNA2CDK2CCNA1SHMT2IKBKB | |
| SCHEMBL21625120 | 0.66 | SHMT2 (0.43) | CCNA2CDK2CCNA1SHMT2 | |
| SCHEMBL21625198 | 0.64 | SHMT2 (0.50) | CCNA2CDK2CCNA1SHMT2 | |
| SCHEMBL21625118 | 0.64 | SHMT2 (0.50) | SHMT2 | |
| SCHEMBL21625174 | 0.64 | SHMT2 (0.50) | SHMT2 | |
| SCHEMBL6659189 | 0.64 | CCNA2 (0.64) | CCNA2CDK2CCNA1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020016315-A1 | FUSED DIHYDROINDAZOLE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-01-23 | — | — | WO | disclosed |